401567-36-0

Basic information

• Product Name: 6-fluoro-2-(piperazin-1-yl)benzo[d]thiazole
• Synonyms: 6-fluoro-2-(piperazin-1-yl)benzo[d]thiazole
• CAS NO: 401567-36-0
• Molecular Weight: 237.301
• Mol File: 401567-36-0.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 6-fluoro-2-(piperazin-1-yl)benzo[d]thiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-fluoro-2-(piperazin-1-yl)benzo[d]thiazole(401567-36-0)
• EPA Substance Registry System: 6-fluoro-2-(piperazin-1-yl)benzo[d]thiazole(401567-36-0)

Safety Data

• Hazardous Substances Data: 401567-36-0(Hazardous Substances Data)

Usage

Chemical Class

Benzothiazole derivative

Molecular Structure

Contains a fluorine atom and a piperazine ring

Pharmacological Activities

Potential antimicrobial, antiviral, and antipsychotic activities

Applications

Widely used as a building block in the synthesis of pharmaceuticals and agrochemicals

Medical Research

Investigated for the treatment of anxiety, depression, and other medical conditions

Biological Imaging

Potential use as a fluorescent probe in biological imaging

Coordination Chemistry

Explored as a ligand in coordination chemistry studies

Upstream product

• 152937-04-7 2-bromo-6-fluorobenzo[d]thiazole 
• 399-74-6 2-chloro-6-fluorobenzothiazole 
• 110-85-0 piperazine 
• 348-40-3 2-amino-6-fluoro-1,3-benzothiazole 

Relevant articles and documents

Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof

The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

2-Substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and preparation method and application thereof

The invention discloses 2-substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and a preparation method and application thereof, and particularly, relates to 2-substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue with a formula (I) compound and a preparation method and application thereof, wherein substitutions in the formula (I) compound are defined as in the description. This serial compound can inhibit the activity of glycine transport protein-1 (GlyT1), is useful in treating related diseases in central nerve and psychological fields, for example, schizophrenia (including positive symptoms, negative symptoms and cognitive symptoms), senile dementia, Parkinson's disease and other related psychological diseases, is widely applicable to the drugs for preventing and treating central nerve and psychological diseases, and is expected to be developed into new-generation GlyT1 inhibitors.

Small molecules enhance functional O-mannosylation of Alpha-dystroglycan

Alpha-dystroglycan (α-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of α-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of α-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of α-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of α-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of α-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of α-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy.